Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland. Swiss Med Wkly [Internet]. 2019 Dec. 27 [cited 2025 Oct. 14];149(5152):w20170. Available from: https://www.smw.ch/index.php/smw/article/view/2711